Sinovac Biotech vs Zai Lab
SVA and ZLAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SVA and ZLAB compare
Sinovac Biotech grew revenue faster over the last twelve months (6.8% versus 5.1% for Zai Lab).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SVA | ZLAB |
|---|---|---|
| Size and price | ||
| Market cap | – | $36.5B |
| Share price | $6.47 | $23.47 |
| Change, 1 year | 0.00% | 8.0% |
| Change, 5 years | 0.00% | −69.5% |
| Beta (5Y) | 0.00 | 1.46 |
| Employees | 2,602 | 1,784 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 3 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 81.1× |
| P/B | – | 60.0× |
| FCF yield | – | −0.38% |
| Fair value | – | $4.52 |
| Margin of safety | – | −420% |
| Growth | ||
| Revenue growth (TTM) | 6.8% (better) | 5.1% |
| Revenue growth, 5Y average | −5.4% | 56.5% (better) |
| EPS growth (TTM) | −165% | – |
| Profitability | ||
| Gross margin | 67.9% (better) | 56.5% |
| Operating margin | −127% | −58.7% (better) |
| Net margin | – | −41.9% |
| FCF margin | −145% | −31.0% (better) |
| Return on equity | – | −26.9% |
| Return on invested capital | – | −90.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.39 (better) |
| Interest coverage | – | −44.1× |
| Current ratio | 4.59 (better) | 2.13 |
| Altman Z-score | – | 43.35 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Years of dividend growth | 0 | – |
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 14.6% | 2.8% |
| Held by insiders | 65.7% | 0.67% |
| Insider net buying, 12 months | – | −$10.7M |
| Short interest, % of float | 0.33% | – |
Go deeper
- SVA stock overview
- SVA income statement
- SVA valuation and score
- ZLAB stock overview
- ZLAB income statement
- ZLAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.